68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma
Drug Design, Development and Therapy · 2026
DOI: 10.2147/dddt.s646346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Jiaojiao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Lutetium, Antibodies, Monoclonal, Humanized. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, People's Republic of China.
- Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, People's Republic of China.
- Department of Nuclear Medicine, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Anhui, 230001, People's Republic of China.
- Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
ORCID-Profile: Ao Li
Zitieren
APA
Li, J., Yang, X., Li, A., Li, R., Wang, T., Dong, X., Li, X., Xie, Q., Zuo, C., & Zhang, W. (2026). 68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s646346
Vancouver
Li J, Yang X, Li A, Li R, Wang T, Dong X, et al. 68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s646346
BibTeX
@article{Li2026,
author = {Li, Jiaojiao and Yang, Xiao and Li, Ao and Li, Rou and Wang, Tao and Dong, Xiaoxu and Li, Xiao and Xie, Qiang and Zuo, Changjing and Zhang, Wei},
title = {68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma},
journal = {Drug Design, Development and Therapy},
year = {2026},
doi = {10.2147/dddt.s646346}
}
EUVIMED